Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Preferentially Expressed Antigen of Melanoma (PRAME)-Specific Cytotoxic T-Lymphocytes (CTLs) and Transgenic T Cells To Target Chronic Myelogenous Leukemia (CML).

C. Quintarelli, PhD, G. Dotti, MD, B. De Angelis, PhD, V. Hoyos, MD, M. Mims, MD, F. Pane, MD, Helen E. Heslop, MD, C.M. Rooney, PhD, M.K. Brenner, MD, B. Savoldo, MD

Blood (2007) 110 (11): 2761.

https://doi.org/10.1182/blood.V110.11.2761.2761

Published: 2007

Journal Articles

High-Resolution Genomic Profiling of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) Identified Novel Recurrent Copy Number Variations Involved in Both Pathogenesis and Resistance to Tyrosine Kinase Inhibitors.

Ilaria Iacobucci, E. Ottaviani, A. Astolfi, S. Soverini, N. Testoni, S. Paolini, P.P. Piccaluga, C. Papayannidis, D. Cilloni, A. Pession, F. Pane, A. Vitale, S. Chiaretti, R. Foà, M. Baccarani, Giovanni Martinelli

Blood (2007) 110 (11): 230.

https://doi.org/10.1182/blood.V110.11.230.230

Published: 2007

Journal Articles

The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors.

Blood (2007) 110 (11): 722.

https://doi.org/10.1182/blood.V110.11.722.722

Published: 2007

Journal Articles

Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.

Ilaria Iacobucci, Giovanni Martinelli, M. Amabile, A. Poerio, S. Soverini, F. Castagnetti, S. Colarossi, A. Gnani, N. Testoni, M. Breccia, E. Abruzzese, B. Martino, D. Cilloni, G. Saglio, F. Pane, G. Rosti, M. Baccarani

Blood (2006) 108 (11): 2156.

https://doi.org/10.1182/blood.V108.11.2156.2156

Published: 2006

Journal Articles

Prognostic Impact of Genetic Characterization in the GIMEMA LAM99P Study for Newly Diagnosed Adult AML. Relevance of Combined Analysis of Conventional Karyotyping, FLT3 and NPM Mutational Status.

Blood (2005) 106 (11): 226.

https://doi.org/10.1182/blood.V106.11.226.226

Published: 2005

Journal Articles

Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

G. Cimino, MD, L. Elia, PHD, G. Meloni, MD, L. Annino, MD, A. Chiarenza, MD, G. Martinelli, MD, F. Pane, MD, M. Montanaro, MD, P. Chiusolo, MD, A. Santoro, MD, M. Offidani, MD, M. Vignetti, MD, G. Saglio, MD, M. Baccarni, MD, F. Mandelli, MD, Robert Foa, MD

Blood (2004) 104 (11): 1082.

https://doi.org/10.1182/blood.V104.11.1082.1082

Published: 2004

Journal Articles

Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) [see comments]

F Pane, F Frigeri, M Sindona, L Luciano, F Ferrara, R Cimino, G Meloni, G Saglio, F Salvatore, B Rotoli

Blood (1996) 88 (7): 2410–2414.

https://doi.org/10.1182/blood.V88.7.2410.bloodjournal8872410

Published: 1996

Journal Articles

Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis

G Saglio, F Pane, E Gottardi, F Frigeri, MR Buonaiuto, A Guerrasio, D de Micheli, A Parziale, MN Fornaci, G Martinelli, F Salvatore

Blood (1996) 87 (3): 1075–1080.

https://doi.org/10.1182/blood.V87.3.1075.bloodjournal8731075

Published: 1996

NARROW

Preferentially Expressed Antigen of Melanoma (PRAME)-Specific Cytotoxic T-Lymphocytes (CTLs) and Transgenic T Cells To Target Chronic Myelogenous Leukemia (CML).

High-Resolution Genomic Profiling of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) Identified Novel Recurrent Copy Number Variations Involved in Both Pathogenesis and Resistance to Tyrosine Kinase Inhibitors.

The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors.

Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.

Prognostic Impact of Genetic Characterization in the GIMEMA LAM99P Study for Newly Diagnosed Adult AML. Relevance of Combined Analysis of Conventional Karyotyping, FLT3 and NPM Mutational Status.

Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) [see comments]

Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only